Prediction of drug–ABC-transporter interaction — Recent advances and future challenges☆

With the discovery of P-glycoprotein (P-gp), it became evident that ABC-transporters play a vital role in bioavailability and toxicity of drugs. They prevent intracellular accumulation of toxic compounds, which renders them a major defense mechanism against xenotoxic compounds. Their expression in cells of all major barriers (intestine, blood–brain barrier, blood–placenta barrier) as well as in metabolic organs (liver, kidney) also explains their influence on the ADMET properties of drugs and drug candidates. Thus, in silico models for the prediction of the probability of a compound to interact with P-gp or analogous transporters are of high value in the early phase of the drug discovery process. Within this review, we highlight recent developments in the area, with a special focus on the molecular basis of drug–transporter interaction. In addition, with the recent availability of X-ray structures of several ABC-transporters, also structure-based design methods have been applied and will be addressed.

[1]  G. Ecker,et al.  Predicting Ligand Interactions with ABC Transporters in ADME , 2009, Chemistry & biodiversity.

[2]  Peter W Swaan,et al.  Computational approaches to modeling drug transporters. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[3]  K. Yoshioka,et al.  Mutational analysis of the MRP2 gene and long-term follow-up of Dubin-Johnson syndrome in Japan , 2005, Journal of Gastroenterology.

[4]  S. Chong,et al.  P-gp Inhibition Potential in Cell-Based Models: Which “Calculation” Method is the Most Accurate? , 2008, The AAPS Journal.

[5]  Gerhard F. Ecker,et al.  Computational models for prediction of interactions with ABC-transporters. , 2008, Drug discovery today.

[6]  F. Sharom,et al.  Lipid bilayer properties control membrane partitioning, binding, and transport of p-glycoprotein substrates. , 2013, Biochemistry.

[7]  Guidance for Industry Drug Interaction Studies — Study Design , Data Analysis , Implications for Dosing , and Labeling Recommendations , 2022 .

[8]  R. Béliveau,et al.  Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. , 2002, Vascular pharmacology.

[9]  P. Bungay,et al.  Minimizing Drug Exposure in the CNS while Maintaining Good Oral Absorption. , 2012, ACS medicinal chemistry letters.

[10]  Gerhard F. Ecker,et al.  Exhaustive Sampling of Docking Poses Reveals Binding Hypotheses for Propafenone Type Inhibitors of P-Glycoprotein , 2011, PLoS Comput. Biol..

[11]  A. di Pietro,et al.  Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Callaghan,et al.  How can we best use structural information on P-glycoprotein to design inhibitors? , 2007, Pharmacology & therapeutics.

[13]  Stephen G Aller,et al.  Refined structures of mouse P-glycoprotein , 2013, Protein science : a publication of the Protein Society.

[14]  Peter W Swaan,et al.  Identification of novel breast cancer resistance protein (BCRP) inhibitors by virtual screening. , 2013, Molecular pharmaceutics.

[15]  Giuseppe Trapani,et al.  New strategies to deliver anticancer drugs to brain tumors , 2009, Expert opinion on drug delivery.

[16]  A. Kaddoumi,et al.  Role of ABC transporters in the pathogenesis of Alzheimer's disease. , 2012, ACS chemical neuroscience.

[17]  Dan Li,et al.  ADMET evaluation in drug discovery. 13. Development of in silico prediction models for P-glycoprotein substrates. , 2014, Molecular pharmaceutics.

[18]  M. Jamei,et al.  Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria , 2013, Drug Metabolism and Disposition.

[19]  Teruaki Okuda,et al.  Clarification of P-glycoprotein inhibition-related drug–drug interaction risks based on a literature search of the clinical information , 2014, Xenobiotica; the fate of foreign compounds in biological systems.

[20]  G J Williams,et al.  The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1978, Archives of biochemistry and biophysics.

[21]  Stephen A. Wring,et al.  Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.

[22]  S. Paine,et al.  Can long range mechanical interaction between drugs and membrane proteins define the notion of molecular promiscuity? Application to P-glycoprotein-mediated multidrug resistance (MDR). , 2013, Biochimica et biophysica acta.

[23]  Jue Chen,et al.  Crystal structure of the multidrug transporter P-glycoprotein from C. elegans , 2012, Nature.

[24]  M. Hohl,et al.  Crystal structure of a heterodimeric ABC transporter in its inward-facing conformation , 2012, Nature Structural &Molecular Biology.

[25]  J. G. Kenna,et al.  In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in Humans , 2012, Drug Metabolism and Disposition.

[26]  Gerhard F. Ecker,et al.  Studies on propafenone-type modulators of multidrug resistance VI. Synthesis and pharmacological activity of compounds with varied spacer length between the central aromatic ring and the nitrogen atom , 1998 .

[27]  M. X. Fernandes,et al.  New Uses for Old Drugs: Pharmacophore‐Based Screening for the Discovery of P‐Glycoprotein Inhibitors , 2011, Chemical biology & drug design.

[28]  Tingjun Hou,et al.  ADME evaluation in drug discovery , 2002, Journal of molecular modeling.

[29]  Lei Chen,et al.  ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naive Bayesian classification techniques. , 2011, Molecular pharmaceutics.

[30]  H K Kroemer,et al.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.

[31]  Ricardo J. Ferreira,et al.  Insights on P-Glycoprotein's Efflux Mechanism Obtained by Molecular Dynamics Simulations. , 2012, Journal of chemical theory and computation.

[32]  Christel A. S. Bergström,et al.  Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). , 2008, Journal of medicinal chemistry.

[33]  A. Harris,et al.  Reversal of multidrug resistance by verapamil and modulation by alpha 1-acid glycoprotein in wild-type and multidrug-resistant Chinese hamster ovary cell lines. , 1990, Cancer research.

[34]  Zsolt Bikádi,et al.  Predicting substrates of the human breast cancer resistance protein using a support vector machine method , 2013, BMC Bioinformatics.

[35]  John N Weinstein,et al.  Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.

[36]  T. Davis,et al.  P-glycoprotein Modulates Morphine Uptake into the CNS: A Role for the Non-steroidal Anti-inflammatory Drug Diclofenac , 2014, PloS one.

[37]  D. K. Williams,et al.  Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. , 2008, Molecular nutrition & food research.

[38]  F. Russel,et al.  In silico identification and in vitro validation of potential cholestatic compounds through 3D ligand-based pharmacophore modeling of BSEP inhibitors. , 2014, Chemical research in toxicology.

[39]  Yue Weng,et al.  Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.

[40]  Tudor I. Oprea,et al.  A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. , 2011, Journal of medicinal chemistry.

[41]  Gerhard F. Ecker,et al.  Ligand and Structure-Based Classification Models for Prediction of P-Glycoprotein Inhibitors , 2013, J. Chem. Inf. Model..

[42]  Yan Li,et al.  Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2). , 2013, Food chemistry.

[43]  Leslie Z. Benet,et al.  Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.

[44]  Ricardo J. Ferreira,et al.  Molecular Docking Characterizes Substrate-Binding Sites and Efflux Modulation Mechanisms within P-Glycoprotein , 2013, J. Chem. Inf. Model..

[45]  K. Locher,et al.  Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP‐PNP , 2007, FEBS letters.

[46]  C. Scharinger,et al.  A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities , 2014, European Neuropsychopharmacology.

[47]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[48]  Andreas Bender,et al.  P-glycoprotein Substrate Models Using Support Vector Machines Based on a Comprehensive Data set , 2011, J. Chem. Inf. Model..

[49]  G. Ecker,et al.  Structure–Activity Relationships, Ligand Efficiency, and Lipophilic Efficiency Profiles of Benzophenone-Type Inhibitors of the Multidrug Transporter P-Glycoprotein , 2012, Journal of medicinal chemistry.

[50]  Ricardo J. Ferreira,et al.  Toward a Better Pharmacophore Description of P-Glycoprotein Modulators, Based on Macrocyclic Diterpenes from Euphorbia Species , 2011, J. Chem. Inf. Model..

[51]  A. Barr,et al.  Structures of ABCB10, a human ATP-binding cassette transporter in apo- and nucleotide-bound states , 2013, Proceedings of the National Academy of Sciences.

[52]  Floriane Montanari,et al.  BCRP Inhibition: from Data Collection to Ligand‐Based Modeling , 2014, Molecular informatics.

[53]  Katrin Wlcek,et al.  ATP‐binding cassette transporters in liver , 2014, BioFactors.

[54]  Hassane S. Mchaourab,et al.  On the Origin of Large Flexibility of P-glycoprotein in the Inward-facing State* , 2013, The Journal of Biological Chemistry.

[55]  E. Pardon,et al.  Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain , 2013, Proceedings of the National Academy of Sciences.

[56]  Peter A. Edwards,et al.  Role of ABC transporters in lipid transport and human disease , 2013, Trends in Endocrinology & Metabolism.

[57]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[58]  Chris T. A. Evelo,et al.  Applying linked data approaches to pharmacology: Architectural decisions and implementation , 2014, Semantic Web.

[59]  G R Wilkinson,et al.  Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[60]  Louis-David Cantin,et al.  Mitigating the Inhibition of Human Bile Salt Export Pump by Drugs: Opportunities Provided by Physicochemical Property Modulation, In Silico Modeling, and Structural Modification , 2012, Drug Metabolism and Disposition.

[61]  D. Duś,et al.  8-Prenylnaringenin is an inhibitor of multidrug resistance-associated transporters, P-glycoprotein and MRP1. , 2010, European journal of pharmacology.

[62]  Gerhard F Ecker,et al.  An In Silico Classification Model for Putative ABCC2 Substrates , 2012, Molecular informatics.

[63]  N. Shaik,et al.  Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design , 2009, Drug Metabolism and Disposition.

[64]  R. Dawson,et al.  Structure of a bacterial multidrug ABC transporter , 2006, Nature.

[65]  M. Trauner,et al.  The Role of Canalicular ABC Transporters in Cholestasis , 2014, Drug Metabolism and Disposition.

[66]  A. di Pietro,et al.  C-Isoprenylation of flavonoids enhances binding affinity toward P-glycoprotein and modulation of cancer cell chemoresistance. , 2001, Journal of medicinal chemistry.

[67]  N. Shinomiya,et al.  ABCG2/BCRP Dysfunction as a Major Cause of Gout , 2011, Nucleosides, nucleotides & nucleic acids.

[68]  Lei Chen,et al.  Computational models for predicting substrates or inhibitors of P-glycoprotein. , 2012, Drug discovery today.

[69]  J. Dodge,et al.  Structure/activity relationships , 1998 .

[70]  T. Ranheim,et al.  Tangier disease caused by compound heterozygosity for ABCA1 mutations R282X and Y1532C. , 2010, Atherosclerosis.

[71]  Sean Ekins,et al.  Pharmacophore-based discovery of ligands for drug transporters. , 2006, Advanced drug delivery reviews.

[72]  J. Beijnen,et al.  Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699) , 2014, Pharmaceutical Research.

[73]  Hui Zhang,et al.  Support vector machine and pharmacophore-based prediction models of multidrug-resistance protein 2 (MRP2) inhibitors. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[74]  Evan Bolton,et al.  PubChem's BioAssay Database , 2011, Nucleic Acids Res..

[75]  K. Linton,et al.  AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Molecular Mechanistic Explanation for the Spectrum of Cholestatic Disease Caused by the S320F Variant of ABCB4 , 2014 .

[76]  Matthew P. Jacobson,et al.  Predicting Binding to P-Glycoprotein by Flexible Receptor Docking , 2011, PLoS Comput. Biol..

[77]  A. Tropsha,et al.  Human Intestinal Transporter Database: QSAR Modeling and Virtual Profiling of Drug Uptake, Efflux and Interactions , 2013, Pharmaceutical Research.

[78]  R. Stroud,et al.  Subnanometre-resolution electron cryomicroscopy structure of a heterodimeric ABC exporter , 2014, Nature.

[79]  S-M Huang,et al.  Why Clinical Modulation of Efflux Transport at the Human Blood–Brain Barrier Is Unlikely: The ITC Evidence‐Based Position , 2013, Clinical pharmacology and therapeutics.

[80]  Marilyn E. Morris,et al.  Structure–Activity Relationships and Quantitative Structure–Activity Relationships for Breast Cancer Resistance Protein (ABCG2) , 2009, The AAPS Journal.

[81]  J. Beijnen,et al.  P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387. , 2013, Pharmacological research.

[82]  Ulf Norinder,et al.  Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs , 2009, Pharmaceutical Research.

[83]  W. Dalton,et al.  Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. , 1991, Blood.

[84]  Paola Vergani,et al.  The ABC protein turned chloride channel whose failure causes cystic fibrosis , 2006, Nature.

[85]  Barbara Zdrazil,et al.  Annotating Human P-Glycoprotein Bioassay Data , 2012, Molecular informatics.

[86]  Vasilis Vasiliou,et al.  Human ATP-binding cassette (ABC) transporter family , 2009, Human Genomics.

[87]  Geoffrey Chang,et al.  Flexibility in the ABC transporter MsbA: Alternating access with a twist , 2007, Proceedings of the National Academy of Sciences.